CD274 and undifferentiated pleomorphic sarcoma: The anti-PDL1 atezolizumab is effective in patients with alveolar soft part tissue sarcoma [29], while other ICIs have shown promising efficacy in a subset of patients with undifferentiated pleomorphic sarcoma (UPS) [30] and angiosarcoma, especially in cutaneous angiosarcoma of the head and neck [31,32].